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Introduction: Patients with young stroke remain at substantial risk of developing recurrent vascular events and 
information on very long-term prognosis and its risk factors is indispensable. Our aim is to investigate this very 
long-term risk and associated risk factors up to 35 years after stroke. 
Patients and methods: Prospective cohort study among 656 patients with first-ever ischemic stroke or TIA, 
aged 18-50, who visited our hospital (1980–2010). Outcomes assessed at follow-up (2014-2015) included TIA or 
ischemic stroke and other arterial events, whichever occurred first. Kaplan-Meier analysis quantified cumulative 
risks. A prediction model was constructed to asses risk factors independently associated with any ischemic event 
using Cox proportional hazard analyses followed by bootstrap validation procedure to avoid overestimation. 
Results: Mean follow-up was 12.4 (SD 8.2) years (8105 person-years). 25-years cumulative risk was 45.4% 
(95%CI 39.4-51.5) for any ischemic event, 30.1% (95%CI 24.8-35.4) for cerebral ischemia and 27.0% (95%CI 
21.1-33.0) for other arterial events. Risk factors retained in the prediction model were smoking (HR 1.35, 95%CI 
1.04-1.74), poor kidney function (HR 2.10, 95%CI 1.32-3.35), history of peripheral arterial disease (HR 2.10, 
95%CI 1.08-3.76) and cardiac disease (HR 1.84, 95%CI 1.06-3.18) (C-statistic 0.59 (95%CI 0.55-0.64). 
Discussion and conclusion: Young stroke patients remain at substantial risk for recurrent events; almost 1 of 2 
develops a recurrent ischemic event and 1 of 3 develops a recurrent stroke or TIA during 25 years of follow-up. 
Risk factors independently associated with recurrent events were poor kidney function, smoking, history of 






Long-term prognosis after a stroke at young age is significantly affected by occurrence of incident vascular 
events. It is already known that this risk is not only high in the first months or years after stroke, but patients 
remain at a substantial risk even 10 years after their initial stroke.1 
Reliable information thereafter is largely lacking, though important to know as after 10 years these patients are 
still young and usually have a life expectancy of yet decades ahead. Providing young adults with reliable 
information on the course of their disease, including the risk factors associated with this prognosis, also after the 
first 10 years is therefore of utmost importance.  
Only a few large studies have tried to identify which particular risk factors were associated with recurrent 
vascular events. However in those studies mean follow-up did not exceed 5 year2, 3, or only the association 
between the etiologic subgroups based on TOAST-classification and recurrent events was taken into account 
rather than subgroups based on (potentially modifiable) risk factors.4 Also, prognosis has only been examined for 
the overall stroke population. Though this is important information from health care perspective, this does not 
always answer the question of individual patients who have a particular interest in their own, personalized 
prognosis. One study did develop a score for individual risk estimation of recurrent thrombotic events, with a 
moderate predictive value and follow-up duration of more than 3 years.2 Especially for younger patients, an 
individualized long-term risk assessment, after this first years after stroke is also of great importance.  
Therefore, aims of this study were to investigate the very long-term risk of recurrent vascular events up to 35 
years after a stroke at young age. In addition, we aimed to identify risk factors independently associated with the 
risk of recurrent vascular events on the long-term. Subsequently, predictive performance of the resulting model 
was assessed.  
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Patients and methods 
Study population 
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and Unelucidated Risk 
factor Evaluation”-study (FUTURE-study), a prospective cohort study on causes and consequences of a stroke 
in young adults.5 Detailed methods have been described previously.1 The Medical Review Ethics Committee 
region Arnhem-Nijmegen approved the study. All patients signed informed consent.  
In the present study we included all consecutive patients with a first-ever TIA or ischemic stroke, aged 18-50 
years, admitted to the Radboud University Nijmegen Medical Centre from 1980 till 2010. The World Health 
Organization definition for TIA and stroke was used.6  
Patients were identified through a prospective registry with standardized collection of baseline characteristics. 
Cardiovascular risk factors were defined as a history of a risk factor or detected during analysis of the initial 
event: hypertension as mean systolic blood pressure ≥135 mmHg or a diastolic blood pressure of ≥85 mmHg, 
measured after the first week of the index event7 or the use of antihypertensive medication; diabetes mellitus as 
random blood glucose level >200 mg/dL (11.1 mmol/L) or two consecutive fasting venous plasma glucose levels 
≥6.1 mg/dL (7.0 mmol/L)8 or the use of antidiabetics; dyslipidemia as total cholesterol ≥5.0 mmol/L, LDL ≥2.5 
mmol/L or triglycerides ≥2.0 mmol/L1 or the use of statins; smoking as at least 1 cigarette per day in the year 
prior to the event; atrial fibrillation when identified on electrocardiogram or during continuous 
electrocardiographic recording; excess alcohol consumption as consuming more than 200 g of pure alcohol per 
week. Kidney function was divided in estimated glomerular filtration rate (eGFR) <60, eGFR 60-120 and 
eGFR>120 mL/min/1.73m2.9 In addition, a history of cardiovascular disease (myocardial infarction, cardiac 
intervention procedures and peripheral artery revascularization procedures) was collected. 
The assessment of stroke etiology (Trial of Org 10172 in Acute Stroke Treatment (TOAST))10 and severity 
(National Institutes of Health Stroke Scale11) was done for all cases retrospectively by a validated approach.12 
 
Follow-up 
Follow-up assessment took place from 2009 to 2012 and subsequently from August 2014 to January 2015. In 
case information from this last follow-up assessment was missing, follow-up data from the previous follow-up 
(2009-2012) were used (n=28, 4.3%). Patients underwent structured questionnaires on the occurrence of 
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recurrent events. In case a patient had died, information was retrieved by the general practitioner. All confirmed 
events were verified by a neurologist or cardiologist. TIA and ischemic stroke were defined similar to the index 
event, myocardial infarction was defined according to the universal definition of myocardial infarction.13  
 
Outcome 
Primary outcome was the risk of any recurrent ischemic event, defined as the composite of cerebral ischemia 
(ischemic stroke or TIA) and other arterial events (myocardial infarction, coronary artery bypass grafting, 
percutaneous coronary intervention, carotid endarterectomy or peripheral artery revascularization procedures). 
Secondary outcomes were the risk of recurrent cerebral ischemia and the risk of other arterial events.  
 
Statistical analysis 
Kaplan-Meier analysis was used to estimate cumulative risks of any ischemic event, cerebral ischemia and other 
arterial event, whichever occurred first. Person-years at risk were calculated for each patient from date of the 
index stroke until recurrent event, death or end of follow-up. Patients who died and/or did not reach an endpoint 
were censored. Survival plots were curtailed at 25 years to ensure that the provided survival plots were reliable 
for all subgroups14, all events were retained in subsequent analyses. Analyses were stratified by stroke subtype, 
age categories (18-29, 30-39 and 40-50 years) and TOAST-subtype with undetermined cause as reference. 
Annual risks were calculated from survival estimates obtained by Kaplan-Meier analysis. Mean annual risks 
were subsequently calculated for the periods 2-5 years, 6-10 years, 11-15 years, 16-20 years and 21-25 years. 
Missing data were handled using multiple imputation by the method of chained equations (eGFR 29.9% and 
dyslipidemia 20%.)15, under the assumption that missing data was missing at random. 30 imputed datasets were 
created using predictive mean matching for eGFR and logistic regression for dyslipidemia. All variables 
considered in the subsequent regression analyses were included in the imputation model. Regression analyses 
were performed on each of the imputed datasets individually and subsequently the coefficients were pooled 
using Rubin’s rules.16 Restricting the analyses to only complete patients, yielded similar point estimates as 
obtained in the imputed datasets. Cox proportional hazard analysis was used to calculate hazard ratios with their 
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95% confidence intervals (CI’s) for baseline characteristics adjusted for age and sex for the risk of any ischemic 
event, cerebral ischemia and other arterial events. 
A composite variable with number of traditional risk factors was used (diabetes mellitus, hypertension, smoking, 
dyslipidemia or atrial fibrillation).  
Finally we constructed a multivariable Cox regression model to predict recurrent ischemic events. All predictors 
were considered for entrance in the models irrespective of their univariable association with the outcome.  
Subsequently, the model was simplified using a backward selection procedure (exclusion if p<0.20). 
A bootstrap validation procedure (b=100) was performed to avoid overestimation in regression coefficients.17 A 
shrinkage factor was derived from this procedure and subsequently applied to the regression coefficients. 
Discriminative performance of the model was assessed by calculating the concordance (c) statics. Also the c-
statistic was corrected for overoptimism by applying the bootstrap validation procedure. All p-values of less than 
0.05 were considered as significant. IBM SPSS 20.0 and R version 3.2.1 software package (packages MICE 






656 patients entered present study, 209 (31.9%) patients with TIA and 447 (61.7%) patients with ischemic 
stroke. Mean follow-up was 12.4 (SD8.6) years and 21.3% had a follow-up of more than 20 years. At the end of 
follow-up 167 (25.5%) patients were deceased. Baseline characteristics are shown in table 1. 
There were no differences in baseline characteristics between participants and non-participants (lost to follow-up 
n=73 and refusers n=139) except for age (39.1 years (SD8.2) versus 40.7 years (SD7.7) respectively). 
 
Cumulative risk of ischemic events 
During 8105 person-years of follow up, 197 (30%) patients had at least one ischemic event of whom 67 (34.0%) 
had more than one event.  
25-years cumulative risk of any ischemic event was 45.4% (95%CI 39.4-51.5), 30.1% (95%CI 24.8-35.4) for 
cerebral ischemia and 27.0% (95% CI 21.1-33.0) for other arterial events (Figure 1A-C). There was no sex 
difference. Annual risks are shown in figure 2.  
There were no differences between patients with a TIA or ischemic stroke with regards to their 25-years 
cumulative risk of any ischemic event (TIA 40.7% (95%CI 29.7-46.4) and ischemic stroke 47.1% (95%CI 40.0-
50.8), cerebral ischemia (TIA 27.8% (95%CI 23.0-37.0) and ischemic stroke 30.8% (95%CI 27.6-37.2), or other 
arterial events (TIA 23.7% (95%CI 18.3-34.2) and ischemic stroke 28.5% (95%CI 24.9-35.8). 
There were no differences in 25-years cumulative risk of any ischemic event or cerebral ischemia by age 
category. Patients aged 40-50 years at the time of their qualifying stroke at young age had a higher 25-years 
cumulative risk of other arterial events (38.2%, 95%CI 28.9-47.6) compared to patients aged 30-39 years 
(15.5%, 95%CI 7.2-23.7) (log rank p=0.004) and patients aged 18-29 years (7.8%, 95%CI 0.3-15.4) (log rank 
p=0.002). 
Figure 3 shows the cumulative risk of any ischemic event stratified by TOAST-subtype. For cerebral ischemia, 
patients with a cardio-embolic stroke (50.8%, 95%CI 25.8-75.7) or small vessel disease (37.5%, 95%CI 22.7-
52.4) had a higher 25-years cumulative risk than patients with undetermined cause (22.9%, 95% 15.2-30.6) (Log 
rank p=0.02 and p=0.02 respectively). For other arterial events patients with a large artery stroke (48.5, 95%CI 
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37.8-59.2) or cardio-embolic stroke (60.9, 95%CI 6.0-115.8) had a higher 25-years cumulative risk than those 
with undetermined cause (17.3, 95%CI 8.6-26.1) (Log rank p<0.001 and p=0.05 respectively).  
 
Risk factors 
In age- and sex-adjusted univariable analyses, age (HR 1.03 per year increase, 95%CI 1.01-1.05), diabetes 
mellitus (HR 1.62, 95%CI 1.03-2.57), hypertension (HR 1.36, 95%CI 1.02-1.82 ), eGFR <60 (2.51, 95%CI 1.47-
4.26, history of PAD (HR 3.44, 95%CI 21.95-6.08) and history of cardiac disease (HR 3.33, 95%CI 2.01-5.52) 
were associated with any ischemic event. In addition, number of traditional risk factors was associated with any 
ischemic event (Table 2). 
Kidney function (eGFR < 60) was associated with recurrent cerebral ischemia (HR 3.18, 95%CI 1.74-5.80). 
Factors associated with other arterial event were age (HR 1.08 per year increase, 95%CI 1.04-1.11), diabetes 
mellitus (HR 2.54, 95%CI 1.42-4.52), hypertension (HR 1.61, 95%CI 1.06-2.43), smoking (HR 2.12, 95%CI 
1.32-3.42), history of PAD (HR 6.87, 95%CI 3.60-13.12) and cardiac disease (HR 4.99, 95%CI 2.70-9.21). 
Table 3 shows the multivariable Cox proportional hazard model. Smoking (HR 1.35, 95%CI 1.04-1.74), 
eGFR<60 (HR 2.10, 95%CI 1.32-3.35), history of PAD (HR 2.10, 95%CI 1.08-3.76) and cardiac disease (HR 
1.84, 95%CI 1.06-3.18) were independently associated with any ischemic event. Reported hazard ratios have 
been shrunk by applying a shrinkage factor of 0.82 derived from the bootstrap validation procedure. C-statistic 





We showed that patients with a stroke at young age remain at a high risk of developing recurrent ischemic 
events, even decades after their stroke. Traditional vascular risk factors are common in these patients and are 
associated with this life-long risk.  
A unique and essential strength of our study is the large study population in combination with a very long-term 
follow-up duration up to 35 years. For patients with a stroke at young age, a long-term risk assessment is crucial, 
as patients are still young after only a few years of follow-up. Moreover, the single centre, prospective design, 
made it possible to uniformly collect data, making information bias less likely.  
However, some possible limitations need to be addressed. First of all selection bias might have occurred as 
patients who did not participate in the study might have been the ones with a more severe outcome. The number 
of patients who refused to participate and those lost to follow-up is rather high, which is probably due to the long 
follow-up duration, however there were no differences in baseline characteristics, making selection bias less 
likely. 
Second, since our study features a long inclusion period, recall bias may have influenced our findings, especially 
when patients experienced their event a long time ago or died, however, this would only have resulted in an 
underestimation of cumulative incidence. In addition, we have tried to overcome this by collecting information 
in an identical way in patients who died and those still alive. Along the course of the inclusion period, specific 
young stroke investigations might have changed and secondary prevention strategies changed over time, which 
might have influenced risk of recurrent vascular events. However, these are unavoidable features of a long-term 
follow-up study.  
We have previously shown that patients with a stroke at young age remain at a high risk of developing recurrent 
vascular events.1 Due to the extension of our follow up we were now able to show that even up to 25 years after 
stroke at a young age risk of recurrent events remains high. Moreover we found an even higher risk compared to 
other large cohorts2-4, 18-20, most likely due to the far longer follow-up duration and inclusion of TIA as an 
outcome event in our cohort. In addition, most other studies were small and/or retrospective.3, 18-20 
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To determine secondary prevention strategies and provide information on the course of the disease for individual 
patients, it is necessary to assess risk of recurrent events at an individual level and treatment decisions should 
ideally be based on clinical trials. As younger patients were usually underrepresented in trials on secondary 
prevention21, it remains uncertain how to treat these patients and information should be obtained from large 
cohorts.22 We therefore aimed to identify risk factors associated with recurrent vascular events. Poor kidney 
function, smoking and a history of PAD and cardiac disease were independently associated with recurrent 
ischemic events. However the prediction model only had a moderate discriminative ability. Possible reasons for 
this finding might include residual confounding which might have arisen from inevitable differences in 
measurement of risk factors during the course of an inclusion period spanning almost 30 years. Furthermore due 
to the long inclusion period in our cohort, secondary prevention strategies changed, which may have influenced 
the prediction model as well.  
Two previous studies also tried to identify risk factors associated with recurrent vascular events. One study 
found age, heart failure, previous TIA and diabetes mellitus to be important predictors3 while the other 
prospective study found especially discontinuation of medication, antiphospholipid antibodies, family history, 
migraine with aura and any increase in traditional vascular risk factors to be associated with recurrent events2. 
However, follow-up in those studies was shorter and they had a smaller number of events to include in the 
analyses. Differences in study design and inclusion criteria between the studies could have contributed to the 
variation in associated risk factors. Patients in our study and the Finnish study were older (41.5 years) than in the 
Italian stroke project (36.8 years), which may have resulted in a higher incidence of traditional risk factors. In 
addition, it may be possible that due to the longer follow-up duration, traditional vascular risk factors become 
more important as patients are longer exposed to the risk factors. In addition, the Italian study developed a score 
for individual risk estimation, with a better predictive value than the prediction model in our study (c-statistic 
0.66). Unfortunately, none of the models had a good discriminative ability, which may also indicate that there is 
considerable potential to be gained. Other unknown factors may contribute to the risk of recurrent events. For 
example, increasing evidence suggests that stroke at a young age has a stronger genetic basis than stroke 
occurring at older ages.23, 24 Genetic factors might also interact with vascular risk factors, possible making 
patients with a stroke at young age more vulnerable to traditional vascular risk factors. 
Furthermore we found that patients with a cardio-embolic stroke or large artery disease had a higher risk of any 
ischemic event or other arterial event. Another large study on the association between etiologic subgroups and 
recurrent events, also found large artery atherosclerosis and cardioembolism to be important predictors of 
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recurrent events.4 Moreover, in our study patients with small vessel disease or large artery disease had a higher 
risk of recurrent ischemia. This is probably explained by the fact that patients with these etiologies of their 
stroke, are more likely to have traditional risk factors than patients with an undetermined cause. Surprisingly, age 
was not associated with the risk of recurrent events, which indicates that even very young patients remain at a 
substantial risk of developing recurrent vascular events. 
Our findings may indicate that risk factors for vascular diseases and a history of vascular diseases such as 
peripheral artery or cardiac disease, should create awareness among the treating physician for risk of future 
recurrent events. Especially smoking is an important modifiable risk factor, which can be addressed more 
straightforward than pre-existing atherosclerosis in daily practice. Although prediction models are not perfect, 
traditional vascular (partly) modifiable risk factors do seem to play an important role in developing recurrent 
events. This might suggest that strict long-term secondary prevention strategies should be encouraged, even in 
very young patients, however it should be noted that the use and adherence of medication is not taken into 
account in this study. Therefore future research should especially aim at secondary prevention strategies in this 
specific age group. 
In conclusion, we have shown that patients with a stroke at young age remain at substantial risk for developing 
recurrent vascular events, even decades after their initial event. Particularly young patients, with vascular risk 
factors that are usually prevalent at higher ages should raise the level of suspicion of their treating physicians as 
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Figure 1. Cumulative risks of ischemic events 
1A. Any ischemic event  
1B. Cerebral ischemia  
1C. Other arterial events  
 
Figure 2. Annual risk of ischemic events 
Data points represent mean annual risks for the periods 2 to 5 years, 6 to 10 years, 11 to 15 years, 16 to 20 years 
and 21 to 25 years. 
 
Figure 3. Cumulative risk of any ischemic event stratified by TOAST-subtype 
Patients with large artery (61.4%, 95%CI 51.1%-71.8%) or cardio-embolic stroke (62.7%, 95%CI 38.6%-86.7%) 
had a higher cumulative risk of any ischemic event compared to undetermined cause (33.8%, 95%CI 24.3%-














Mean age at time of event, years [SD] 40.7 (7.7) 40.6 (8.0) 40.8 (7.6) 
Men, n (%) 309 (47.1) 94 (45.0) 215 (48.1) 
Mean follow-up duration, years [SD] 12.4 (8.6) 11.9 (8.1) 12.6 (8.8) 
 >15 years 217 (33.1) 56 (26.8) 171 (38.3) 
 >20 years 140 (21.3) 41 (19.6) 99 (22.1) 
 >25 years 73 (11.1) 26 (12.4) 47 (10.5) 
Median NIHSS at admission (IQR)a 3 (1-7) 0 (0-1) 5 (2-10) 
TOAST, n. (%)    
 Large artery disease 166 (25.3) 47 (22.5) 119 (26.6) 
 Cardio-embolic stroke 86 (13.1) 27 (12.9) 59 (13.2)  
 Small vessel disease 65 (13.1) 11 (5.3) 54 (12.1) 
 Other defined 96 (14.6) 23 (11.0) 73 (16.3) 
 Multiple causes 17 (2.6) 2 (1.0) 15 (3.4) 
 Unknown 226 (34.5) 99 (47.4) 127 (28.4) 
History of vascular risk factors, n (%)    
 Hypertension 231 (35.2) 71 (34.0) 160 (35.8) 
 Diabetes 54 (8.2) 13 (6.2) 41 (9.2) 
 Dyslipidemiaa 424 (80.8) 147(83.5) 277 (79.4) 
 Atrial fibrillation 15 (2.3) 5 (2.4) 10 (2.2) 
 Smokinga 324 (51.8) 83 (40.7) 241 (57.2) 
 Excess drinking 48 (7.3) 15 (7.2) 33 (7.4) 
Number of traditional risk factorsb    
 0 72 (11.0) 26 (12.4) 46 (10.3) 
 1 243 (37.0) 82 (39.2) 161 (36.0) 
 2 238 (36.3) 71 (34.0) 167 (37.4) 
 ≥3 103 (15.7) 30 (14.4) 73 (16.3) 
History of cardiovascular disease, n (%)c 38 (5.8) 11 (5.3) 27 (6.0) 
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 Cardiac disease 29 (4.4) 9 (4.3) 20 (4.5) 
 Peripheral arterial disease 21 (3.2) 7 (3.3) 14 (3.1) 
Baseline kidney function, n(%)    
 eGFR 60-120 392 (85.2) 122 (88.4) 270 (83.9) 
 eGFR <60 29 (6.3) 7 (5.1) 22 (6.8) 
 eGFR >120 39 (8.5) 9 (6.5) 30 (9.3) 
Abbreviations: TIA, transient ischemic attack; NIHSS, national institutes of health stroke scale; IQR, 
interquartile range 
aMissing data: NIHSS 0.5%; dyslipidemia 20%; smoking 4.7%; eGFR 29.9%. 
bRisk factors included diabetes mellitus, hypertension, dyslipidemia, atrial fibrillation and smoking. 
cSome patients both had a history of PAD and cardiac disease 
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Table 2   Univariate age- and sex-adjusted associations with recurrent vascular events 
 Any ischemic event Cerebral ischemia Other arterial events 
 HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Sex, men 0.91 (0.68-1.21) 0.50 0.94 (0.67-1.33) 0.73 0.77 (0.51-1.17) 0.22 
Age 1.03 (1.01-1.05) 0.01 1.01 (0.99-1.03) 0.35 1.08 (1.04-1.11) <0.001 
Diabetes mellitus 1.62 (1.03-2.57) 0.04 1.24 (0.68-2.26) 0.48 2.54 (1.42-4.52) 0.002 
Hypertension 1.36 (1.02-1.82) 0.04 1.08 (0.75-1.54) 0.68 1.61 (1.06-2.43) 0.02 
Dyslipidemia 1.38 (0.90-2.12) 0.14 1.12 (0.69-1.81) 0.65 1.72 (0.88-3.36) 0.11 
Excess alcohol consumption 0.89 (0.53-1.51) 0.68 0.96 (0.51-1.80) 0.89 1.15 (0.59-2.26) 0.68 
Smoking 1.34 (1.00-1.80) 0.05 1.18 (0.83-1.68) 0.35 2.12 (1.32-3.42) 0.002 
Atrial fibrillation 1.34 (0.55-3.27) 0.52 1.51 (0.55-4.10) 0.42 0.43 (0.06-3.09) 0.40 
Number of traditional risk factors       
 0 1  1    
 1 1.27 (0.57-2.81) 0.55 1.03 (0.46-2.30) 0.94 NA  
 2 2.07 (0.95-4.49) 0.07 1.19 (0.54-2.63) 0.67 NA  
 ≥3 2.54 (1.14-5.66) 0.02 1.46 (0.64-3.35) 0.37 NA  
Baseline kidney function       
 eGFR 60-120 1  1    
 eGFR <60 2.51 (1.47-4.26) 0.001 3.18 (1.74-5.80) <0.001 2.03 (0.92-4.49) 0.08 
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 eGFR >120 0.86 (0.40-1.82) 0.69 1.10 (0.49-2.46) 0.82 0.29 (0.04-2.14) 0.23 
History of cardiovascular disease       
 Peripheral arterial disease 3.44 (1.95-6.08) <0.001 1.38 (0.56-3.39) 0.48 6.87 (3.60-13.12) <0.001 
 Cardiac disease 3.33 (2.01-5.52) <0.001 1.80 (0.87-3.74) 0.11 4.99 (2.70-9.21) <0.001 
Age- and sex-adjusted hazard ratios were calculated using Cox proportional hazards analyses. Imputed data were used for missing data. It was not possible to determine 
hazard ratios for ‘number of traditional risk factors’ for the outcome event ‘other arterial events’, due to total separation of the dataset (none of the patients without risk factors 
reached the endpoint ‘other arterial event’).
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Table 3   Predictors of any ischemic event 
  HR (95%CI) p-value 
Age 1.02 (1.00-1.04) 0.06 
Diabetes mellitus 1.39 (0.93-2.07) 0.11 
Alcohol 0.73 (0.47-1.15) 0.18 
Smoking 1.35 (1.04-1.74) 0.02 
Baseline kidney function 
  eGFR 60-120 1 
 eGFR <60 2.10 (1.32-3.35) 0.002 
eGFR >120 0.80 (0.42-1.52) 0.50 
History of peripheral arterial disease 2.01 (1.08-3.76) 0.03 
History of cardiac disease 1.84 (1.06-3.18) 0.03 
Predictors of any ischemic events selected by backward LR (exclusion if p <0.200). C-statistic 0.59 (95%CI 
0.55-0.64). The regression coefficients were corrected for overfitting with a shrinkage factor of 0•82. 
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